1. Home
  2. BGSF vs SCYX Comparison

BGSF vs SCYX Comparison

Compare BGSF & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.05

Market Cap

56.6M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.30

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
SCYX
Founded
2007
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
60.4M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
BGSF
SCYX
Price
$5.05
$4.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
8.4K
288.0K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
$93,310,000.00
$257,000.00
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$0.57
52 Week High
$8.20
$5.62

Technical Indicators

Market Signals
Indicator
BGSF
SCYX
Relative Strength Index (RSI) 42.65 71.37
Support Level $4.97 $0.67
Resistance Level $5.36 $5.62
Average True Range (ATR) 0.18 0.30
MACD 0.02 0.13
Stochastic Oscillator 43.18 72.56

Price Performance

Historical Comparison
BGSF
SCYX

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: